Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease

Takanori Kanai, Yasuhiro Nemoto, Nobuhiko Kamada, Teruji Totsuka, Tadakazu Hisamatsu, Mamoru Watanabe, Toshifumi Hibi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose of review: This review focuses on CD4+ T cells involved in the mediation of inflammatory tissue damage in murine models of inflammatory bowel diseases (IBDs). In particular, we describe the distinct roles of the homeostatic cytokine IL-7, which is essential to the maintenance of colitogenic memory CD4+ cells, and the newly discovered effector cytokine IL-17. We also discuss the close correlation between colitogenic Th17-type CD4 + T cells and inducible CD4+CD25+Foxp3 + regulatory T cells. Recent findings: IBDs are characterized by wasting and chronic intestinal inflammation induced by many different cytokine-mediated pathways. It is clearly recognized that medical and surgical interventions do not cure Crohn's disease because relapse is the rule after remission. Until a few years ago, IBD was classified into Th1-dependent, that is, Crohn's disease, and Th2-dependent, that is, ulcerative colitis, phenotypes. However, in recent years, it has been shown that new T-cell subclasses, that is, Th17 and regulatory T cells (TR), exist independently of Th1 and Th2 and that they play a central role in modulating IBD. Summary: The persistence of IL-7-dependent colitogenic memory CD4+ T cells is critical to the maintenance of experimental colitis. On the other hand, though Th1 and Th2 colitogenic memory CD4+ cells exist, in recent years the central role of IL-17-producing Th17-type cells in IBD has attracted renewed interest. The development of molecularly targeted therapies aimed at a variety of different Th-dependent pathogenic mechanisms may represent a novel approach to IBD therapy.

Original languageEnglish
Pages (from-to)306-313
Number of pages8
JournalCurrent Opinion in Gastroenterology
Volume25
Issue number4
DOIs
Publication statusPublished - 2009 Jul

Fingerprint

Interleukin-7
Interleukin-17
Inflammatory Bowel Diseases
Cytokines
T-Lymphocytes
Regulatory T-Lymphocytes
Crohn Disease
Therapeutics
Maintenance
Th17 Cells
Colitis
Ulcerative Colitis
Inflammation
Phenotype
Recurrence

Keywords

  • Colitogenic memory CD4 T cells
  • IL-7
  • Inflammatory bowel disease
  • Regulatory T cells
  • Th17

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease. / Kanai, Takanori; Nemoto, Yasuhiro; Kamada, Nobuhiko; Totsuka, Teruji; Hisamatsu, Tadakazu; Watanabe, Mamoru; Hibi, Toshifumi.

In: Current Opinion in Gastroenterology, Vol. 25, No. 4, 07.2009, p. 306-313.

Research output: Contribution to journalArticle

Kanai, Takanori ; Nemoto, Yasuhiro ; Kamada, Nobuhiko ; Totsuka, Teruji ; Hisamatsu, Tadakazu ; Watanabe, Mamoru ; Hibi, Toshifumi. / Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease. In: Current Opinion in Gastroenterology. 2009 ; Vol. 25, No. 4. pp. 306-313.
@article{bdf7da38af3a4bf5bfa7d99d224c8d65,
title = "Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease",
abstract = "Purpose of review: This review focuses on CD4+ T cells involved in the mediation of inflammatory tissue damage in murine models of inflammatory bowel diseases (IBDs). In particular, we describe the distinct roles of the homeostatic cytokine IL-7, which is essential to the maintenance of colitogenic memory CD4+ cells, and the newly discovered effector cytokine IL-17. We also discuss the close correlation between colitogenic Th17-type CD4 + T cells and inducible CD4+CD25+Foxp3 + regulatory T cells. Recent findings: IBDs are characterized by wasting and chronic intestinal inflammation induced by many different cytokine-mediated pathways. It is clearly recognized that medical and surgical interventions do not cure Crohn's disease because relapse is the rule after remission. Until a few years ago, IBD was classified into Th1-dependent, that is, Crohn's disease, and Th2-dependent, that is, ulcerative colitis, phenotypes. However, in recent years, it has been shown that new T-cell subclasses, that is, Th17 and regulatory T cells (TR), exist independently of Th1 and Th2 and that they play a central role in modulating IBD. Summary: The persistence of IL-7-dependent colitogenic memory CD4+ T cells is critical to the maintenance of experimental colitis. On the other hand, though Th1 and Th2 colitogenic memory CD4+ cells exist, in recent years the central role of IL-17-producing Th17-type cells in IBD has attracted renewed interest. The development of molecularly targeted therapies aimed at a variety of different Th-dependent pathogenic mechanisms may represent a novel approach to IBD therapy.",
keywords = "Colitogenic memory CD4 T cells, IL-7, Inflammatory bowel disease, Regulatory T cells, Th17",
author = "Takanori Kanai and Yasuhiro Nemoto and Nobuhiko Kamada and Teruji Totsuka and Tadakazu Hisamatsu and Mamoru Watanabe and Toshifumi Hibi",
year = "2009",
month = "7",
doi = "10.1097/MOG.0b013e32832bc627",
language = "English",
volume = "25",
pages = "306--313",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease

AU - Kanai, Takanori

AU - Nemoto, Yasuhiro

AU - Kamada, Nobuhiko

AU - Totsuka, Teruji

AU - Hisamatsu, Tadakazu

AU - Watanabe, Mamoru

AU - Hibi, Toshifumi

PY - 2009/7

Y1 - 2009/7

N2 - Purpose of review: This review focuses on CD4+ T cells involved in the mediation of inflammatory tissue damage in murine models of inflammatory bowel diseases (IBDs). In particular, we describe the distinct roles of the homeostatic cytokine IL-7, which is essential to the maintenance of colitogenic memory CD4+ cells, and the newly discovered effector cytokine IL-17. We also discuss the close correlation between colitogenic Th17-type CD4 + T cells and inducible CD4+CD25+Foxp3 + regulatory T cells. Recent findings: IBDs are characterized by wasting and chronic intestinal inflammation induced by many different cytokine-mediated pathways. It is clearly recognized that medical and surgical interventions do not cure Crohn's disease because relapse is the rule after remission. Until a few years ago, IBD was classified into Th1-dependent, that is, Crohn's disease, and Th2-dependent, that is, ulcerative colitis, phenotypes. However, in recent years, it has been shown that new T-cell subclasses, that is, Th17 and regulatory T cells (TR), exist independently of Th1 and Th2 and that they play a central role in modulating IBD. Summary: The persistence of IL-7-dependent colitogenic memory CD4+ T cells is critical to the maintenance of experimental colitis. On the other hand, though Th1 and Th2 colitogenic memory CD4+ cells exist, in recent years the central role of IL-17-producing Th17-type cells in IBD has attracted renewed interest. The development of molecularly targeted therapies aimed at a variety of different Th-dependent pathogenic mechanisms may represent a novel approach to IBD therapy.

AB - Purpose of review: This review focuses on CD4+ T cells involved in the mediation of inflammatory tissue damage in murine models of inflammatory bowel diseases (IBDs). In particular, we describe the distinct roles of the homeostatic cytokine IL-7, which is essential to the maintenance of colitogenic memory CD4+ cells, and the newly discovered effector cytokine IL-17. We also discuss the close correlation between colitogenic Th17-type CD4 + T cells and inducible CD4+CD25+Foxp3 + regulatory T cells. Recent findings: IBDs are characterized by wasting and chronic intestinal inflammation induced by many different cytokine-mediated pathways. It is clearly recognized that medical and surgical interventions do not cure Crohn's disease because relapse is the rule after remission. Until a few years ago, IBD was classified into Th1-dependent, that is, Crohn's disease, and Th2-dependent, that is, ulcerative colitis, phenotypes. However, in recent years, it has been shown that new T-cell subclasses, that is, Th17 and regulatory T cells (TR), exist independently of Th1 and Th2 and that they play a central role in modulating IBD. Summary: The persistence of IL-7-dependent colitogenic memory CD4+ T cells is critical to the maintenance of experimental colitis. On the other hand, though Th1 and Th2 colitogenic memory CD4+ cells exist, in recent years the central role of IL-17-producing Th17-type cells in IBD has attracted renewed interest. The development of molecularly targeted therapies aimed at a variety of different Th-dependent pathogenic mechanisms may represent a novel approach to IBD therapy.

KW - Colitogenic memory CD4 T cells

KW - IL-7

KW - Inflammatory bowel disease

KW - Regulatory T cells

KW - Th17

UR - http://www.scopus.com/inward/record.url?scp=68049106295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049106295&partnerID=8YFLogxK

U2 - 10.1097/MOG.0b013e32832bc627

DO - 10.1097/MOG.0b013e32832bc627

M3 - Article

VL - 25

SP - 306

EP - 313

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 4

ER -